Eclipsys Releases Financial Results for Quarter Ended June 30, 2007
Boca Raton, FL —August 1, 2007 — Eclipsys Corporation® (NASDAQ: ECLP), The Outcomes Company®, today released results for the quarter ended June 30, 2007.
Second-Quarter Results
Revenues for the quarter ended June 30, 2007, increased by 16.2 percent to $119.0 million, compared with revenues of $102.4 million for the quarter ended June 30, 2006. On a GAAP basis, the second-quarter net income was $5.7 million or $0.11 per share on a basic and diluted basis in 2007 compared to a net income of $1.8 million, or $0.03 per share on a basic and diluted basis in the second quarter of 2006.
Net income for the second quarter of 2007 included stock-based compensation expense of $2.8 million and a $1.2 million expense related to the Company’s voluntary stock option review, primarily for legal and accounting services. Excluding these charges, the Company’s non-GAAP net income was $9.7 million, or $0.18 per share on a basic and diluted basis. Net income for the second-quarter of 2006 included stock-based compensation expense of $2.7 million and a restructuring charge of $1.3 million. Excluding these charges, the Company’s second-quarter 2006 non-GAAP net income was $5.8 million, or $0.11 per share on a basic and diluted basis.
The following table summarizes (unaudited) select financial data:
In thousands, except per share data | |||||||||||||||||||||||||
Three months ended June 30, | Six months ended June 30, | ||||||||||||||||||||||||
2007 | 2006 | $ Change | % Change | 2007 | 2006 | $ Change | % Change | ||||||||||||||||||
Revenues | $ | 119,019 | $ | 102,397 | $ | 16,622 | 16.2 | % | $ | 232,049 | $ | 203,288 | $ | 28,761 | 14.1 | % | |||||||||
Net income (loss) | 5,694 | 1,761 | 3,933 | 223.3 | % | 8,095 | (6,152 | ) | 14,247 | 231.6 | % | ||||||||||||||
Earnings (loss) per common share on a basic and diluted basis | $ | 0.11 | $ | 0.03 | $ | 0.08 | 266.7 | % | $ | 0.15 | ($0.12 | ) | $ | 0.27 | 225.0 | % |
Non-GAAP Results* | Non-GAAP Results* | ||||||||||||||||||||||||
Three months ended June 30, | Six months ended June 30, | ||||||||||||||||||||||||
2007 | 2006 | $ Change | % Change | 2007 | 2006 | $ Change | % Change | ||||||||||||||||||
Revenues | $ | 119,019 | $ | 102,397 | $ | 16,622 | 16.2 | % | $ | 232,049 | $ | 203,288 | $ | 28,761 | 14.1 | % | |||||||||
Net income* | 9,679 | 5,817 | 3,862 | 66.4 | % | 15,799 | 7,902 | 7,897 | 99.9 | % | |||||||||||||||
Earnings per common share, basic* | $ | 0.18 | $ | 0.11 | $ | 0.07 | 63.6 | % | $ | 0.30 | $ | 0.15 | $ | 0.15 | 100.0 | % | |||||||||
Earnings per common share, diluted* | $ | 0.18 | $ | 0.11 | $ | 0.07 | 63.6 | % | $ | 0.29 | $ | 0.15 | $ | 0.14 | 93.3 | % |
*A reconciliation of GAAP to non-GAAP results is included in the attached table.
1750 Clint Moore Road, Boca Raton, FL 33487 • phone 561.322.4321 • fax 561.322.4320 • info@eclipsys.com
Eclipsys Releases Financial Results for Quarter Ended June 30, 2007
August 1, 2007
Page 2 of 3
“The second quarter was one of the strongest in Eclipsys history. We won new clients and expanded our product footprint at many of our existing clients. Our Outcomes Methodology helped us successfully activate our solutions at many clients on-time and on-budget, with high rates of adoption achieved shortly after going live,” said R. Andrew Eckert, president and chief executive officer, Eclipsys Corporation. “The second quarter also marked an important milestone as Sunrise Clinical Manager 4.5 is now live at more than 50 sites with high client satisfaction rates.”
Continued Eckert, “We’ve had a number of specialty sales programs focused on increasing the amount of Eclipsys software and services at our existing clients. Based on the number of contracts we signed this quarter, these programs are beginning to deliver results. Additionally, following our very successful activation of Sunrise Patient Financials and Sunrise Access Management at Kaleida Health, we are seeing increased interest in our revenue cycle and access management solutions.
“This quarter also saw the release of the first annual KLAS 2007 Nursing Adoption of IT Study, where Eclipsys ranked number one in client satisfaction among fully rated vendors. The study also showed that Eclipsys was the only vendor surveyed achieving balanced rates of adoption for physicians and nurses, which we feel enables the level of coordinated care essential to achieving improved outcomes.”
Investor Teleconference August 1
Eclipsys senior executives will discuss the results on a teleconference for investors scheduled for 8:30 a.m. Eastern time on August 1, 2007. Persons interested in participating in the teleconference should call (800) 288-9626 around 15 minutes before the conference is slated to begin. For listen-only mode, participants can go to www.eclipsys.com prior to the conference call to register and download the necessary audio software. An audio replay will be available at www.eclipsys.com approximately 2 hours after the completion of the call on August 1.
Non-GAAP Measures
The financial results reported in this press release have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). In addition to the GAAP results, the Company has provided net income and earnings per share information on a non-GAAP basis for the three month and six month periods ended June 30, 2007 and 2006 to exclude stock-based compensation expenses, expenses related to the Company’s voluntary stock option review and restructuring charges. These non-GAAP financial measures should not be considered a substitute for, or superior to, any measure derived in accordance with GAAP. These non-GAAP financial measures may also be inconsistent with the manner in which similar measures are derived or used by other companies. Internally, management uses this non-GAAP information for forecasting and to help make management decisions, as an indicator of business performance, and to evaluate management’s effectiveness and help determine bonuses for management and others. The economic substance of omitting non-cash stock-based compensation expense in presenting non-GAAP earnings derives from providing investors with consistent measures of performance both before and after including non-cash stock-based compensation charges. The economic substance of omitting the expenses related to the Company’s voluntary stock option review in presenting non-GAAP earnings and restructuring charges derives from the fact that episodic charges of this kind make it more difficult to compare operating results of different periods, not all of which include such expenses and charges. The omission of non-cash stock-based compensation expense may mask an economic cost incurred by the Company in connection with stock-based compensation, and the omission of the expenses related to the Company’s voluntary stock option review and restructuring charges may mask actual and expected future cash expenditures associated with such matters. Management compensates for these limitations by using both the GAAP and non-GAAP measures. Management believes that the non-GAAP financial measures provided, when considered in conjunction with comparable GAAP financial measures, facilitate understanding and evaluation of the Company’s operating performance and future prospects, as well as comparisons of the Company’s results with its prior period results that did not include these charges and with results of other companies on a more consistent basis. Omitting the 2007 expenses related to the Company’s voluntary stock option review facilitates comparison between the 2006 and 2007 periods, as no voluntary stock option review expenses were recorded in the 2006 period. Omitting the 2006 restructuring charges facilitates comparison between the 2006 and 2007 periods, as no restructuring charges were recorded in the 2007 period. Omitting the stock-based compensation expense facilitates review by the majority of the Company’s analysts, who model the Company’s earnings excluding stock-based compensation charges. The Company has provided reconciling information in the attachment to this release.
Eclipsys Releases Financial Results for Quarter Ended June 30, 2007
August 1, 2007
Page 3 of 3
Condensed Consolidated Statement of Cash Flows
The attached Condensed Consolidated Statement of Cash Flows for the six months ended June 30, 2006 has been restated in connection with the Company's restatement of its prior financial statements. For additional information regarding this prior restatement, please refer to Exhibit 99.1 in our Annual Report on Form 10-K for the year ended December 31, 2006, filed on May 23, 2007.
About Eclipsys
Eclipsys is a leading provider of advanced integrated clinical, revenue cycle and access management software, clinical content and professional services that help healthcare organizations improve clinical, financial, operational and client satisfaction outcomes. For more information, see www.eclipsys.com or email info@eclipsys.com.
Statements in this news release or the investor call referenced herein concerning the Company’s sales, marketing and operational initiatives; future financial results, operating performance, and development efforts; and the benefits provided by Eclipsys software and services are forward-looking statements and actual results may differ from those projected due to a variety of risks and uncertainties. Future performance expectations are predicated upon achievement of various sales and performance targets that may be difficult to meet. Sales may be slower than expected due to market conditions, competition, and other factors. Costs may be greater than anticipated due to the potential need to increase spending to ensure performance in accordance with commitments to clients and other factors. Software development may take longer and cost more than expected, and incorporation of anticipated features and functionality may be delayed, due to various factors including programming and integration challenges and resource constraints. The market is highly competitive. Implementation and customization of Eclipsys software is complex and time-consuming. Results depend upon a variety of factors and can vary by client. Each client’s circumstances are unique and may include unforeseen issues that make it more difficult than anticipated to implement or derive benefit from software, implementation or consulting services. The success and timeliness of the Company’s services will depend at least in part upon client involvement, which can be difficult to control. Eclipsys is required to meet specified performance standards, and clients can terminate contracts, assess penalties or reduce contract scope under certain circumstances. More information about company risks is available in recent Form 10-K and other filings made by Eclipsys from time to time with the Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Eclipsys Jason Cigarran Director of Media Relations (media) (561) 322-4355 jason.cigarran@eclipsys.com | Robert J. Colletti Chief Financial Officer (investors) (561) 322-4655 investor.relations@eclipsys.com |
ECLIPSYS CORPORATION AND SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands)
June 30, | December 31, | ||||||
2006 | 2007 | ||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 29,904 | $ | 41,264 | |||
Marketable securities | 104,645 | 89,549 | |||||
Accounts receivable, net of allowance for doubtful accounts of $3,739 and $3,907, respectively | 95,882 | 93,821 | |||||
Inventory | 129 | 1,076 | |||||
Prepaid expenses | 32,486 | 22,947 | |||||
Other current assets | 1,387 | 1,026 | |||||
Total current assets | 264,433 | 249,683 | |||||
Property and equipment, net | 46,248 | 45,806 | |||||
Capitalized software development costs, net | 33,114 | 32,302 | |||||
Acquired technology, net | 896 | 1,224 | |||||
Intangible assets, net | 2,751 | 3,307 | |||||
Deferred tax asset | 3,751 | 3,661 | |||||
Goodwill, net | 14,250 | 12,281 | |||||
Other assets | 15,605 | 15,014 | |||||
Total assets | $ | 381,048 | $ | 363,278 | |||
Liabilities and Stockholders' Equity | |||||||
Current liabilities: | |||||||
Deferred revenue | $ | 97,697 | $ | 103,298 | |||
Accounts payable | 23,776 | 19,879 | |||||
Accrued compensation costs | 14,942 | 12,997 | |||||
Deferred tax liability | 3,827 | 3,699 | |||||
Other current liabilities | 16,579 | 20,213 | |||||
Total current liabilities | 156,821 | 160,086 | |||||
Deferred revenue | 9,458 | 11,289 | |||||
Other long-term liabilities | 1,418 | 1,247 | |||||
Total liabilities | 167,697 | 172,622 | |||||
Stockholders' equity: Total stockholders' equity | 213,351 | 190,656 | |||||
Total liabilities and stockholders' equity | $ | 381,048 | $ | 363,278 |
ECLIPSYS CORPORATION AND SUBSIDIARIES
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except per share amounts)
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||
2007 | 2006 | 2007 | 2006 | ||||||||||
Revenues: | |||||||||||||
Systems and services | $ | 114,266 | $ | 97,821 | $ | 223,292 | $ | 194,151 | |||||
Hardware | 4,753 | 4,576 | 8,757 | 9,137 | |||||||||
Total revenues | 119,019 | 102,397 | 232,049 | 203,288 | |||||||||
Costs and expenses: | |||||||||||||
Cost of systems and services | 67,414 | 58,120 | 131,701 | 114,594 | |||||||||
Cost of hardware | 3,737 | 3,851 | 6,764 | 7,502 | |||||||||
Sales and marketing | 18,034 | 14,531 | 36,172 | 30,741 | |||||||||
Research and development | 13,799 | 14,020 | 28,207 | 30,982 | |||||||||
General and administrative | 7,614 | 6,184 | 15,603 | 11,840 | |||||||||
Depreciation and amortization | 4,296 | 3,894 | 8,571 | 7,696 | |||||||||
Restructuring charge | -- | 1,349 | -- | 8,547 | |||||||||
Total costs and expenses | 114,894 | 101,949 | 227,018 | 211,902 | |||||||||
Income (loss) from operations | |||||||||||||
before interest and taxes | 4,125 | 448 | 5,031 | (8,614 | ) | ||||||||
Interest income, net | 1,588 | 1,313 | 3,102 | 2,462 | |||||||||
Income (loss) before taxes | 5,713 | 1,761 | 8,133 | (6,152 | ) | ||||||||
Provision for income taxes | 19 | -- | 38 | -- | |||||||||
Net income (loss) | $ | 5,694 | $ | 1,761 | $ | 8,095 | $ | (6,152 | ) | ||||
Income (loss) per common share: | |||||||||||||
Basic income (loss) per common | |||||||||||||
share | $ | 0.11 | $ | 0.03 | $ | 0.15 | $ | (0.12 | ) | ||||
Diluted income (loss) per common | |||||||||||||
share | $ | 0.11 | $ | 0.03 | $ | 0.15 | $ | (0.12 | ) | ||||
Weighted average shares | |||||||||||||
outstanding: | |||||||||||||
Basic | 52,596 | 51,598 | 52,471 | 51,109 | |||||||||
Diluted | 53,737 | 52,993 | 53,629 | 51,109 |
ECLIPSYS CORPORATION AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
Six Months Ended | |||||||
June 30, | |||||||
2007 | 2006 | ||||||
As restated | |||||||
Operating activities: | |||||||
Net income (loss) | $ | 8,095 | $ | (6,152 | ) | ||
Adjustments to reconcile net income | |||||||
(loss) to net cash provided by | |||||||
(used in) operating activities: | |||||||
Depreciation and amortization | 19,263 | 18,401 | |||||
Provision for bad debt | 900 | 818 | |||||
Stock compensation expense | 5,547 | 6,669 | |||||
Gain on sale of investments | (10 | ) | -- | ||||
Deferred provision for income | |||||||
taxes | 38 | -- | |||||
Changes in operating assets and | |||||||
liabilities: | |||||||
Decrease (increase) in accounts | |||||||
receivable | (2,126 | ) | 4,418 | ||||
Increase in prepaid expenses and | |||||||
other current assets | (9,724 | ) | (3,242 | ) | |||
Decrease in inventory | 946 | 676 | |||||
Decrease in other assets | 26 | 1,449 | |||||
Decrease in deferred revenue | (7,809 | ) | (13,055 | ) | |||
Increase (decrease) in accrued | |||||||
compensation | 2,394 | (5,907 | ) | ||||
Decrease in accounts payable and | |||||||
other current liabilities | (859 | ) | (4,417 | ) | |||
Increase (decrease) in other | |||||||
long-term liabilities | 65 | (1,095 | ) | ||||
Total adjustments | 8,651 | 4,715 | |||||
Net cash provided by (used | |||||||
in) operating activities | 16,746 | (1,437 | ) | ||||
Investing activities: | |||||||
Purchases of property and | |||||||
equipment | (8,425 | ) | (9,167 | ) | |||
Purchase of marketable securities | (33,999 | ) | (60,621 | ) | |||
Proceeds from sales of marketable | |||||||
securities | 18,898 | 5,700 | |||||
Capitalized software development | |||||||
costs | (9,825 | ) | (4,626 | ) | |||
Change in restricted cash balance | (1,969 | ) | -- | ||||
Cash paid for acquisitions | (686 | ) | (800 | ) | |||
Net cash used in investing | |||||||
activities | (36,006 | ) | (69,514 | ) | |||
Financing activities: | |||||||
Proceeds from stock options | |||||||
exercised | 7,497 | 22,449 | |||||
Proceeds from issuance of common | |||||||
stock in employee | |||||||
stock purchase plan | -- | 223 | |||||
Net cash provided by | |||||||
financing activities | 7,497 | 22,672 | |||||
Effect of exchange rates on cash and | |||||||
cash equivalents | 403 | 174 | |||||
Net decrease in cash and cash | |||||||
equivalents | (11,360 | ) | (48,105 | ) | |||
Cash and cash equivalents - beginning | |||||||
of period | 41,264 | 76,693 | |||||
Cash and cash equivalents - end of | |||||||
period | $ | 29,904 | $ | 28,588 |
ECLIPSYS CORPORATION AND SUBSIDIARIES
Reconciliation of GAAP to Non-GAAP Pro Forma Results
(in thousands, except per share amounts)
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||
2007 | 2006 | 2007 | 2006 | ||||||||||
GAAP net earnings (loss) | $ | 5,694 | $ | 1,761 | $ | 8,095 | $ | (6,152 | ) | ||||
Add back: | |||||||||||||
Stock-based compensation | |||||||||||||
expense (1) | 2,787 | 2,707 | 5,547 | 5,507 | |||||||||
Restructuring charge (2) | -- | 1,349 | -- | 8,547 | |||||||||
Stock option review (3) | 1,198 | -- | 2,157 | -- | |||||||||
Non-GAAP net income (loss) | $ | 9,679 | $ | 5,817 | $ | 15,799 | $ | 7,902 | |||||
GAAP basic earnings (loss) per | |||||||||||||
share | 0.11 | 0.03 | 0.15 | (0.12 | ) | ||||||||
Add back: | |||||||||||||
Stock-based compensation | |||||||||||||
expense (1) | 0.05 | 0.05 | 0.11 | 0.11 | |||||||||
Restructuring charge (2) | -- | 0.03 | -- | 0.16 | |||||||||
Stock option review (3) | 0.02 | -- | 0.04 | -- | |||||||||
Non-GAAP basic earnings per share | $ | 0.18 | $ | 0.11 | $ | 0.30 | $ | 0.15 | |||||
�� | |||||||||||||
GAAP diluted earnings (loss) per | |||||||||||||
share | 0.11 | 0.03 | 0.15 | (0.12 | ) | ||||||||
Add back: | |||||||||||||
Share-based compensation | |||||||||||||
expense (1) | 0.05 | 0.05 | 0.10 | 0.11 | |||||||||
Restructuring charge (2) | -- | 0.03 | -- | 0.16 | |||||||||
Stock option review (3) | 0.02 | -- | 0.04 | -- | |||||||||
Non-GAAP diluted earnings per share | $ | 0.18 | $ | 0.11 | $ | 0.29 | $ | 0.15 |
(1) Relates to stock-based compensation expense and is allocated as follows:
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||
2007 | 2006 | 2007 | 2006 | ||||||||||
Cost of systems & services | $ | 1,099 | $ | 744 | $ | 2,175 | $ | 1,669 | |||||
Sales and marketing | 710 | 890 | 1,680 | 1,688 | |||||||||
Research and development | 573 | 494 | 1,102 | 851 | |||||||||
General and administrative | 405 | 579 | 590 | 1,299 | |||||||||
Total stock-based compensation expense | $ | 2,787 | $ | 2,707 | $ | 5,547 | $ | 5,507 |
(2) | This charge is associated with severance costs related to employment terminations that occurred in the 1st and 2nd quarters of 2006. |
(3) | This charge was incurred in connection with the voluntary stock option review completed in the second quarter of 2007, and primarily relates to legal and accounting fees. |
SOURCE Eclipsys Corporation
-0- 08/01/2007
/CONTACT: Jason Cigarran, Director of Media Relations, +1-561-322-4355, jason.cigarran@eclipsys.com, or Robert J. Colletti, Chief Financial Officer, +1-561-322-4655, investor.relations@eclipsys.com, both of Eclipsys Corporation/
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050209/FLW006LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com/
/Web site: http://www.eclipsys.com/
(ECLP)